Users Coming Off Slimming Medications Put On Pounds Four Times Faster Than Dieters

Fresh analysis reveals that individuals who come off new weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who end conventional diet and exercise programs.

Published data in a major medical journal shows that while overweight individuals can lose a large proportion of their body weight while undergoing treatment, the weight returns at an average rate of nearly a kilo each month upon discontinuation.

"People purchasing such treatments need to be cognizant of the potential of fast rebound weight gain when the medication ends," cautioned expert Dr. Susan Jebb.

This pace of recovery suggests a return to pre-treatment weight within about a year and a half.

Analyzing Therapies

The study, which examined 37 of studies involving over 9,000 of participants, compared the outcomes of the injectable medications with conventional dieting.

Scientists point out that individuals who lose weight through lifestyle changes alone typically experience a slower creep back—perhaps 0.1 kg a month—post-intervention.

Explaining the Rapid Regain

Nutrition scientists propose the way of the drugs explains the accelerated regain.

These medications copy a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.

"Artificially providing GLP-1 levels far above than the body's typical production may cause the system to generate a reduced amount of its endogenous GLP-1, and may also reduce responsiveness to its actions," said Dr. Adam Collins, a nutrition expert.

"Stopping of this GLP-1 'fix' means hunger is no longer kept in check, making overeating much more probable."

A Chronic Condition?

Medical guidelines advise the injections for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.

A number of clinicians argue that, given the high risk of weight regain, the therapy should be considered ongoing.

This view is supported by pharmaceutical companies, who note that the results "emphasize the persistent nature of excess weight," akin to managing conditions like diabetes.

Patient Experiences

Individuals who have discontinued the jabs report a intense return of appetite.

"I experienced something flipping and you become starving," said an individual.

This challenge is exacerbated if patients have not adopted lasting dietary or behavioural modifications during therapy.

Widespread Use

Figures indicate that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow.

• Use is more common among women than males.
• The 40s and 50s demographic shows the highest usage rates.
• A large proportion obtain the drugs through private healthcare rather than the NHS.

Ultimately, experts emphasize that while the jabs are effective agents for shedding pounds, they are not a standalone fix and lasting health benefits relies on integrated behavioural support.